CONFIDENTIAL MATERIAL 
This material is the property of Supernus® Pharmaceuticals, Inc. 
and must not be disclosed or used except as authorized in writing by [CONTACT_364378]® Pharmaceuticals, Inc. 
 
 
 
 
 
 
SUPERNUS® PHARMACEUTICALS, INC.  
STATISTICAL ANALYSIS PLAN  
 
 
 Protocol Number: 810P201  
 
 
A Randomized, Multicenter, Parallel Group, Dose -Ranging Study to 
Evaluate the Safety and Tolerability of SPN -810 in Children with Attention-
Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct 
Problems  
 
 
Version: FINAL Version 1.0 
Date:   31 AUG 2009  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 2 of 33  
 
SIGNATURE [CONTACT_704234].:  810P201  
Protocol Title:  A Randomized, Multicenter, Parallel Group, Dose- Ranging Study to 
Evaluate the Safety and Tolerability of SPN -810 in Children with Attention -
Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct 
Problems  
Drug:  Molindone Hydrochloride  
 
 
 

Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 3 of 33  
 
TABLE OF CONTENTS  
STATISTICAL ANALYSIS PLAN  ....................................................................................................................... 1  
1. INTRODUCTION  ......................................................................................................................................... 7  
2. STUDY OBJECTIVES  ................................................................................................................................ 7  
2.1 PRIMARY OBJECTIVE  ........................................................................................................................... 7  
2.2 SECONDARY OBJECTIVES .................................................................................................................... 7  
3. DESIGN OF THE STUDY  .......................................................................................................................... 7  
3.1 STUDY DESIGN  ..................................................................................................................................... 7  
3.1.1 Screening Period......................................................................................................................... 9  
3.1.2 Titration Period  ............................................................................................................................ 9  
3.1.3 Maintenance Period .................................................................................................................. 10 
3.1.4 Final Visit/Early Termination  .................................................................................................. [ADDRESS_956823] -Study Follow -up Visit  ..................................................................................................... 11 
3.2 SAMPLE SIZE CONSIDERATION  .......................................................................................................... 11 
3.3 RANDOMIZATION PROCEDURE  ........................................................................................................... 11 
3.4 SCHEDULE OF VISITS AND PROCEDURE ............................................................................................ 11 
3.5 EFFICACY MEASURES  ........................................................................................................................ 14 
3.5.1 Primary Efficacy Variable ........................................................................................................ 14 
3.5.2 Secondary Efficacy Variables ................................................................................................ 14 
3.5.3 Exploratory Efficacy Variable  ................................................................................................ 15 
3.6 SAFETY MEASURES  ........................................................................................................................... 15 
3.6.1 Adverse Events  ......................................................................................................................... 15 
3.6.2 Clinical Laboratory Values  ..................................................................................................... 15 
3.6.3 Vital Signs, Height, and Weight Measurements ................................................................ 16 
3.6.4 Medical History and Physical Examinations  ..................................................................... 16 
3.6.5 Electrocardiograms (ECGs)  ................................................................................................... 16 
3.6.6 Concomitant Medications  ....................................................................................................... 17 
3.6.7 Other Special Tests for Extrapyramidal Symptoms (EPS) ............................................. 17 
3.7 COMPLETION /DISCONTINUATION OF SUBJECTS  ............................................................................... [ADDRESS_956824] DISPOSITION ....................................................................................................................... 19 
4.3 DEMOGRAPHICS AND BASELINE CHARACTERISTICS  ......................................................................... 19 
4.4 TREATMENT COMPLIANCE AND EXPOSURE  ....................................................................................... 19 
4.5 POTENTIAL EXCLUSIONS FROM ITT POPULATION  ............................................................................ 19 
4.6 DATA  REVIEW  .................................................................................................................................... 20 
5. EFFICACY ANALYSES  ........................................................................................................................... 20 
5.1 GENERAL CONSIDERA TIONS AND STATISTICAL /ANALYTICAL ISSUES .............................................. 20 
5.1.1 Definition of Baseline ............................................................................................................... 20 
5.1.2 Treatment Comparisons .......................................................................................................... 20 
5.1.3 Pooling of Centers  .................................................................................................................... 21 
5.1.4 Adjustments for Covariates  ................................................................................................... 21 
5.1.5 Multiple Comparisons/Multiplicity ........................................................................................ 21 
5.1.6 Examination of Subgroups ..................................................................................................... 21 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956825] Problem Subscale  ...................................................... 21 
5.2.2 Results of Primary Efficacy Analysis .................................................................................. 22 
5.3 SECONDARY EFFICACY ANALYSES .................................................................................................... 22 
5.3.1 Severity of Illness (CGI -S) ...................................................................................................... 22 
5.3.2 Global Improvement (CGI -I) ................................................................................................... 22 
5.3.3 SNAP -IV Subscale: ADHD -Inattention ................................................................................. 23 
5.3.4 SNAP -IV Subscale: ADHD -Hyperactivity/Impulsivity  ...................................................... 23 
5.3.5 SNAP -IV Subscale: ADHD -Combined Scale  ...................................................................... 23 
5.4 EXPLORA TORY ANALYSES  ................................................................................................................. 24 
5.4.1 SNAP -IV: ODD Subscale ......................................................................................................... 24 
5.4.2 The NCBRF -TIQ Subscales .................................................................................................... 24 
5.5 SENSITIVITY ANALYSIS  ....................................................................................................................... 26 
6. SAFETY ANALYSES  ................................................................................................................................ 27 
6.1 ADVERSE EVENTS  .............................................................................................................................. 27 
6.1.1 Overall Study.............................................................................................................................. 27 
6.1.2 By [CONTACT_704217]/Baseline Variables ................................................................................... 27 
6.1.3 Deaths, Serious AEs, and Other Significant AEs ............................................................. 28 
6.2 CLINICAL LABORATORY VALUES  ....................................................................................................... 28 
6.3 VITAL SIGNS, HEIGHT , WEIGHT AND BMI .......................................................................................... 28 
6.4 ECG  RESULTS  ................................................................................................................................... 28 
6.5 PHYSICAL EXAMINATION  .................................................................................................................... 28 
6.6 CONCOMITANT MEDICATIONS  ............................................................................................................ 28 
6.7 OTHER SAFETY ANALYSES FOR EXTRAPYRAMIDAL SYMPTOMS (EPS)  ........................................... 29 
6.7.1 Simpson- Angus Scale (SAS)  ................................................................................................. 29 
6.7.2 Barnes Akathisia Scale (BAS)  ............................................................................................... 29 
6.7.3 Abnormal Involuntary Movement Scale (AIMS)  ................................................................ [ADDRESS_956826] (DSMB)  ................................................................................ 29 
8. PROGRAMMING  SPECIFICATIONS  .................................................................................................... 30 
8.1 FORMAT OF TABLES AND LISTINGS  ................................................................................................... 30 
8.1.1 Title of a Table/Listing .............................................................................................................. 30 
8.1.2 Footnotes to a Table/Listing  .................................................................................................. 31 
8.1.3 Header and Footer  .................................................................................................................... 32 
8.2 DATA FORM AT  .................................................................................................................................... 32 
8.3 CODING LISTS  .................................................................................................................................... 32 
9. SUMMARY TABLES, DATA LISTINGS AND FIGURES (TLFS)  ...................................................... 33 
10. REFERENCES ...................................................................................................................................... 33 
11. FINAL VERSION REVISION HISTORY  ........................................................................................... 33 
12. APPENDICES  ....................................................................................................................................... 33 
12.1 APPENDIX I: DATA REVIEW MEETING MINUTES  ................................................................................ 33 
12.2 APPENDIX II: REPORT TO THE FIRST MEETING OF THE DSMB ....................................................... 33 
12.3 APPENDIX III: REPORT TO THE SECOND MEETING OF THE DSMB .................................................. 33 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956827] aspartate transaminase  
ATC Anatomical -Therapeutic -Chemical  
AUC  area under the plasma concentration versus time curve  
AUC ss area under the concentration -time curve at steady state  
BAS Barnes Akathisia Scale  
BID two times per day  
BUN  blood urea nitrogen  
CFR Code of Federal Regulations  
CGI Clinical Global Impression  
CGI-S Clinical Global Impression – Severity of Illness  
CGI- I  Clinical Global Impression – Global Improvement  
CL/F  apparent oral clearance  
CRA  Clinical Research Associate  
CRF  Case Report Form  
CRO  Contract Research Organization  
Css avg average steady -state concentration  
DBD  Disruptive Behavior Disorder  
DSMB  Data Safety Monitoring Board  
DSM -IV-TR Diagnostic and Statistical Manual of Mental Disorders – Text Revision  
ECG  electrocardiogram  
EEG  electroencephalogram  
EPS extrapyramidal symptoms  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
HR Heart rate  
IAF Informed Assent Form  
ICD-[ADDRESS_956828]  Schedule for Affective Disorders and Schizophrenia for School -aged 
Children—Present and Lifetime Versions  
LNH Low, normal, high  
MedDRA  Medical Dictionary for Regulatory Activities  
NCBRF -TIQ Nisonger Child Behavior Rating Form - Typi[INVESTIGATOR_704212], Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 6 of 33  
 
PK-PD  pharmacokinetic -pharmacodynamic  
PO orally  
QHS  at bedtime  
QTcF  QT corrected using Fridericia's method  
RBC  red blood cell  
SAE serious adverse event  
SAP Statistical Analysis Plan  
SAS Simpson- Angus Scale  
SM study medication  
SNAP- IV Swanson, Nolan and Pelham Rating Scale- Revised  
SOC  System Organ Class  
SOP  Standard Operating Procedure  
TDD Total Daily Dose  
TEAE  treatment -emergent adverse event  
TEOSS Treatment of Early Onset Schizophrenia Spectrum Disorders  
TESS  Treatment -emergent signs and symptoms  
TID three times per day  
US [LOCATION_002]  
WBC  white blood cell  
WHO -DD World Health Organization Drug Dictionary  
 
 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 7 of 33  
 
1. INTRODUCTION  
The purpose of this statistical analysis plan (SAP) is to reasonably ensure that the tables  
and data listings  which will be produced, and statistical methodologies that will be used, are 
complete and allow for the arrival at valid conclusions regarding the study objectives. In the 
development of this SAP, the following documents were used:  
 
• The Final Protocol 810P201 (Amendment 1), Version 2.0, 09- SEP- 2008  
• Case Report Forms, Version 1.0, [ADDRESS_956829] problems.  
2.2 S ECONDARY OBJECTIVE S 
• To explore the relationship between SPN -810 plasma concentration exposure and 
safety and tolerability endpoints.  
• To assess the effect of SPN -[ADDRESS_956830] problem subscale of the Nisonger Child Behavior  Rating 
Form -Typi[INVESTIGATOR_345644]  (NCBRF -TIQ) after [ADDRESS_956831] problems.  To determine eligibility for the study, subjects will 
undergo an initial screening visit.  Seventy -two subjects will be randomized in the study; 
assuming a 17% dropout rate, it is anticipated that [ADDRESS_956832] of a Screening Period (within [ADDRESS_956833] dose administration), a Titration Period of [ADDRESS_956834] duration in the study will be 16 to 19 weeks  depending on the treatment group 
assignment.  The total study duration is anticipated to be 15.5 months.  
A total of 72 subjects will be randomized based on weight at baseline, to 1 of 4 treatment groups.  A dose titration schedule will be followed ( Table 1), where dosing for subjects < 
30kg will be initiated at 1.67mg/day and dosing for subjects ≥ 30kg or more will be initiated 
at 3.34mg/day.  The titration schedule will be followed until the target dose (Treatment 1, 2, 3, or 4) is reached.  Subjects will remain at the target dose for 6 weeks.  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956835]’s next 
maintenance dose of Study Medication (SM) will be administered in the clinic.  The first PK draw will be a trough sample just prior to dosing.  The dose will be administered, and a 
second draw will be performed between [ADDRESS_956836] dose (Treatment 3) will be permitted per subject.  Benztropi[INVESTIGATOR_704213] (EPS), at a starting 
dose of 0.5mg BID up to a range of 1 to 4mg/day.  
3.1.[ADDRESS_956837] dose administration to 
determine subjects’ eligibility to participate in the study.  Prior to conducting any screening procedures, written informed consent/assent must be obtained from the parent or LAR, and 
subject (when required).  
The NCBRF -TIQ will be administered to determine eligibility.  The diagnosis of ADHD will be 
confirmed with the Schedule
 for Affective Disorders and Schizophrenia for School -aged 
Children—Present and Lifetime Versions (K -SADS- PL).   The Introductory and Screen 
Interviews will be completed.  The Screen Interview will determine which Supplements 
should be completed.  Supplement 4 (Behavioral Disorders) must be completed to assess ADHD, ODD and CD.  If an exclusionary diagnosis is confirmed, the remainder of the 
diagnostic will not be completed.  
Other procedures to be performed will include the collection of medical history and 
demographic data, physical examination, collection of vital signs, height, and weight, 
electrocardiogram (ECG), blood collection for hematology and chemistry, urine collection for 
urinalysis, drug screen, and pregnancy test (for female subjects of menstruating age or ≥  11 
years old).  The Kaufman Brief Intelligence Test, Second Edition (KBIT -2) should be 
administered if an IQ test has not been performed within the past 12 months prior to 
screening.  Concomitant medication and AE information will be collected once informed 
consent/assent is obtained.  
Unscheduled visits may be conducted at the discretion of the investigator throughout all 
study periods.  The medical monitor should be notified promptly of any need for an 
unscheduled visit.  
3.1.[ADDRESS_956838] Titration Period visit (Baseline).  Subjects < 
30kg will be assigned a 1.67mg/day dose (1 week) followed by a 3.34mg/day dose (1 week) 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 10 of 33  
 
followed by [CONTACT_102073] 5mg/day or continued titration up to 10, 15 or 20mg/day.  
Subjects ≥ 30kg or more will be assigned a 3.34mg/day dose (1 week) followed by a 
5mg/day dose (1 week) followed by [CONTACT_102073] 10mg/day or continued titration 
up to 20, 30, or 40mg/day.   
Baseline safety (including Simpson -Angus  Scale [SAS] , Barnes  Akathisia Scale [BAS] , 
Abnormal Involuntary Movement Scale [AIMS]) and efficacy assessments (including 
NCBRF -TIQ, Clinical Global Impression [CGI] and Swanson, Nolan and Pelham Rating 
Scale - Revised [SNAP -IV]) will be performed.  Inclusion/Exclusion criteria should be re-
assessed at this visit.  Concomitant medication and AE information will be collected.  
After the first Titration Period visit, subjects will return to the study site weekly for dose 
increases, monitoring of AEs, and the administration of safety and efficacy scales.  Procedures to be performed are collection of vital signs and weight, and PK blood sampling (at Weeks 2 and 3).  Assessments of concomitant medications and drug compliance will be 
performed.  
3.1.3 Maintenance Period  
Following dose titration, subjects will be maintained at their designated dose level for 6 
weeks.  Subjects will return to the study site weekly for monitoring of AEs and the administration of efficacy and safety scales.  Procedures to be performed are collection of 
vital signs and weight at each visit, and blood collection for hematology and chemistry and 
urine collection for urinalysis (Week 2 only).  PK blood sampling will be performed at Week [ADDRESS_956839] dose group (Treatment 4) will be permitted to down titrate once at the Investigator’s discretion in consultation with the Medical Monitor.  If this down- titration occurs 
outside a scheduled visit, the subject should be brought into the clinic for evaluation.   
For all unscheduled visits, including those unrelated to down- titration, AEs should be 
documented and vital signs collected.  Relevant safety scales should be completed at the 
discretion of the investigator.  
3.1.4 Final Visit/Early Termination  
Subjects will return to the study site for a final visit, after completing the [ADDRESS_956840] 
(for female subjects of menstruating age or ≥  11 years old).  PK blood sampling will be 
performed, with a first draw at trough drug levels prior to dosing, followed by [CONTACT_704218] a second draw [ADDRESS_956841] -dose.  Assessments of concomitant 
medications and drug compliance will be performed.  
 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956842]’s last dose  will 
be collected.  All new SAEs will be collected, and reported if the event is at least possibly 
related to SM.   AEs or SAEs that are ongoing at the subject’s last study visit must be 
followed until resolution or if, in the medical judgment of the Investigator , the event has 
stabilized or is assessed as chronic.  
3.2 SAMPLE SIZE CONSIDERA TION 
Seventy -two subjects will be randomized in the study. Assuming a 17% dropout rate, it is 
anticipated that 60 subjects will complete the study.  The sample size is not based on any statistical considerations, but it was judged adequate to provide safety, PK, and efficacy 
information for a proof -of-concept study.     
 
3.3 RANDOMIZATION PROCEDURE  
The randomization for this study will be managed centrally by [CONTACT_704219]; specific 
instructions to conduct subject randomization will be provided in a separate document to all 
investigational sites, along with site staff access to the system.  
A randomization scheme will be generated using a pseudo- random number generator in a 
computer program.  The method avoids bias by [CONTACT_2363] a chance mechanism.   Within each 
weight group, the randomization scheme assigns Treatment 1, Treatment 2, Treatment 3, or Treatment 4 to each randomization number in a 1:1:1:[ADDRESS_956843] is withdrawn.  All subjects are randomized only 
once.  
3.4 SCHEDULE OF VISITS AND PROCEDURE  
All subjects who are rand omized  and take any SM will be followed according to the protocol , 
unless consent for follow -up is withdrawn.  The Sponsor, or the Sponsor’s designee, must 
be notified of all deviations from the protocol visits or procedures and these procedures, if 
applicable, will be rescheduled or performed at the nearest possible time to the original 
schedule.  
The exhibit on the next page presents the schedule of visits and procedures for the study.  
 
 
Supernus Pharmaceuticals, Inc.  CONFIDENTIAL  31 AUG 2009 
Statistical Analysis Plan (Protocol: 810P201) FINAL Version 1.0 Page 12 of 33 
__________________________________________________________________________________________________________________________  
 
CONFIDENTIAL MATERIAL 
This material is the property of Supernus® Pharmaceuticals, Inc. 
and must not be disclosed or used except as authorized in writing by [CONTACT_364378]® Pharmaceuticals, Inc. 
 Exhibit:  Schedule of Visits and Procedures  
PERIOD Screening  Titration  Maintenance  Final  
Visitk Follow -
up 
VISIT  0 1 2 3 b 4 c 5 d 6 7 8 9 10 11 12 13 
WEEK  0 1 2 3 b 4 c 5 d 1 2 3 4 5 6 7  
WINDOW (DAYS) Within 28  days 
prior to dosing  ±  1 ±  1 ±  1 ±  1 ±  1 ±  2 ±  2 ±  2 ±  2 ±  2 ±  2 ±  2 ±  3   
Informed Consent /Assenta X              
IVRS Call  X X           X  
K-SADS -PL X              
IQ Test (KBIT -2)e X              
Inclusion/Exclusion Criteria  X X             
Randomization   X             
Medical History  X              
Demographic s X              
Physical Exam ination  X            X  
ECG (12 -lead)  X            X  
Vital Signs, height, and weight f X X X X X X X X X X X X X  
Hematology/chemistry  X       X     X  
Urinalysis  X       X     X  
PK Blood Sampling    X X     Xi      Xi  
Urine Drug Screen  X            X  
Urine  Pregnancy Testg X            X  
Efficacy Scales  (NCBRF-TIQ , CGI, SNAP -IV) Xh X X X X X X X X X X X X  
Safety Scales  (Simpson -Angus, Barnes, AIMS)   X X X X X X X X X X X X  
Adverse Events   Xj X X X X X X X X X X X X Xl 
Concomitant Medication s X X X X X X X X X X X X X  
Drug Return and Compliance    X X X X X X X X X X X  
Drug Dispens ation   X X X X X X X X X X X   
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956844] to be administered if not performed 12 months prior to screening. 
f Heart rate (H R), blood pressure, temperature, respi[INVESTIGATOR_697] , and weight will be measured  weekly. Height will only be measured at Screening and Final Visit. 
g To be performed for female subjects  of menstruating age or ≥  [ADDRESS_956845]’s next maintenance dose is observed in clinic between [ADDRESS_956846] be followed until resolution, stabilization, or assessed as chronic .  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956847] Problem subscale score is the primary efficacy variable.   
The ratings from the NCBRF -TIQ scale are grouped into a single 10- item Positive Social 
subscale and the following 6 Problem Behavior Subscales: Overly Sensitive (4 items), 
Oppositional Behavior (9 items), Conduct Problem  (14 items), Hyperactivity (4 items), 
Inattention (7 items), and Withdrawal/Dysphoria  (16 items).  
Each subscale score is the sum of the scores for the individual items included in the 
subscale. The Oppositional Behavior and Conduct Problem subscale totals can be 
combined into a DBD -Total score, and the Hyperactivity and Inattention subscales can be 
combined into an ADHD -Total score.  
3.5.2 Secondary Efficacy Variables  
CGI- S, CGI- I, ADHD -Inattention, ADHD -Hyperactivity/Impulsivity, and ADHD- Combined 
Subscale scores are the 5 secondary efficacy variables as described below.  
 The CGI scale was developed to provide a brief, stand- alone assessment of the clinician’s 
view of a subject’s global functioning prior to and after administration of a SM.  Severity of 
illness (CGI -S) and global improvement (CGI -I) are both rated on a scale of 0 to 7 with 7 
being “extremely ill” or “very much worse”, respectively.  Successful therapy is indicated by a lower overall score in subsequent testing.   
• CGI- S will be evaluated by [CONTACT_345699] a 7 -point scale with 
1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill.   CGI- S is a secondary efficacy variable.  
• CGI- I, relative to the condition at baseline, will be evaluated by [CONTACT_385579] -baseline visit on a 7- point scale with 1=Very much improved, 2=Much 
improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very much worse.    CGI -I is a secondary efficacy variable.  
 
The SNAP -IV rating scale includes 18 ADHD and 8 oppositional defiant disorder (ODD) 
symptoms as specified in the DSM -IV-TR and International Statistical Classification of 
Diseases and Health Related Problems 10th Revision  (ICD-10) Classification of Mental and 
Behavioral Disorders.  The symptoms are scored by [CONTACT_20526] a severity estimate for each symptom on a 4- point scale.    
 
The ratings from the SNAP -IV scale are grouped into the following 3 subscales:  ADHD -
Inattention (items #1 -9), ADHD- Hyperactivity/Impulsivity (items #10 -18), and ODD (items 
#19-26).  In addition, the first two subscales are combined to form the ADHD -Combined 
subscale.  Each subscale score is the average of the scores for the individual items included 
in the subscale.   
 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 15 of 33  
 
3.5.3 Exploratory Efficacy Variable  
The ODD subscale score (items #19 -26 from the SNAP -IV scale)  is an exploratory efficacy 
variable.  
NCBRF -TIQ subscale ( Overly Sensitive  Oppositional , Hyperactivity ,Inattention, and 
Withdrawal/Dysphoria) scores  are considered exploratory efficacy variables. Additional 
exploratory variables will be the DBD- Total score, and the ADHD -Total score from the 
NCBRF -TIQ. 
3.[ADDRESS_956848] of AE and SAE monitoring, clinical laboratory 
tests, vital signs, physical examinations, and 12 -lead ECGs.  Assessment of possible 
neurological side effects will be performed using the Simpson- Angus scale, Barnes Akathisia 
scale, and AIMS.  
3.6.1 Adverse Events  
For subjects who receive SM, all AEs (learned of through spontaneous reports or subject interview) will be collected starting from providing informed consent for study participation.  Collection will continue through [ADDRESS_956849] dose of SM for non -serious AEs, and 
through the 30 day Follow -up Visit for SAEs.  All AEs will be collected on the AE Case 
Report Form (CRF).  SAEs will be  reported if the Investigator believes the event is at least 
possibly related to SM.   Investigator will assess the severity and the causality of AEs.  
A cluster of signs and symptoms that results from a single cause should be reported as a 
single AE (e.g., fever, elevated WBC, cough, abnormal chest X -ray, etc. can all be reported 
as “pneumonia”).  
3.6.[ADDRESS_956850] s should be performed under fasting 
conditions .  Any laboratory abnormality may qualify as an AE in the Investigator’s judgment.  
A complete list of all clinical laboratory assessments is presented in Table below.  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 16 of 33  
 
Hematology  Serum Chemistry (fasting)  Urinalysis 
Hematocrit  
Hemoglobin 
Red blood cell count (RBC)  
Platelet count  
White blood cell count (WBC) (with differential)  
 Albumin  
Alkaline phosphatase  
Alanine transaminase (ALT)  
Aspartate transaminase (AST)  
Bilirubin - Total and Direct  
Blood urea nitrogen (BUN)  
Calcium  
Chloride  
Cholesterol - Total, HDL and LDL  
Creatinine  
Creatine phosphokinase (CPK)  
Glucose Inorganic phosphorous  
Potassium 
Sodium  
Total protein Triglycerides  
Uric acid  Ketones  
Protein 
Specific gravity  
Glucose 
pH 
 
Other tests 
Insulin  
Prolactin 
Urine drug panel for drugs of abuse (amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, marijuana/cannabinoids, 
methadone, opi[INVESTIGATOR_858], phencyclidine, propoxyphene, and alcohol)  
Urine pregnancy test (for female subjects of menstruating age or ≥ 11 years old)  
 
3.6.3 Vital Signs, Height, and Weight  Measurements  
Vital sign measurements (HR, blood pressure, temperature, respi[INVESTIGATOR_697]) and height and 
weight will be obtained at all visits as designated on the Schedule of Visits and Procedures.  
Blood pressure and pulse will be measured after the subject has been sitting  for 5 minutes.  
Pulse should not be recorded on Screening and Final Visits when ECGs are performed.  
3.6.4 Medical History and Physical Examinations 
Medical history will be taken at the screening visit.  Physical examinations will be performed 
at the Screening visit and Final Visit as designated on the Schedule of Visits and 
Procedures.  
3.6.5 Electrocardiograms (ECGs)   
ECGs (12 -lead) will be obtained at the Screening visit and the Final Visit as designated on 
the Schedule of Visits and Procedures.  Additional ECGs may be performed at other times if deemed necessary.  
The ECG will be recorded while the subject is resting in a supi[INVESTIGATOR_2547].  The ECG will 
electronically measure the PR, QRS, QT, and QTc intervals, and heart rate.  
All ECG tracings will be reviewed within 24 hours by [CONTACT_137996]- Investigator.  PR 
intervals will be determined for each of these ECGs from a single reading.  Invalid 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 17 of 33  
 
measurements will be repeated.  QTc will be reported as QTcF ( QT corrected using 
Fridericia's method).  
3.6.[ADDRESS_956851] the AE for which the 
concomitant medication was administered on the AE CRF.  
3.6.7 Other Special Tests for Extrapyramidal Symptoms (EPS)  
Simpson- Angus Scale  
The Simpson- Angus scale is a 10- item rating scale that is widely used for assessment of 
neuroleptic -induced Parkinsonism.  It consists of [ADDRESS_956852] -screening study visits.  
Abnormal Involuntary Movement Scale (AIMS)  
The AIMS test is a rating scale used to measure tardive dyskinesia.  There are [ADDRESS_956853]’s body.  This assessment will be 
administered at all post -screening study visits. 
3.7 C OMPLETION /DISCONTINUATION OF SUBJECTS  
Subjects will be permitted to leave the study at any time.  Subjects can be withdrawn from 
the study in any of the following circumstances:  
• SAE or an AE 
• Administrative reasons (e.g., sponsor decision)  
• Withdrawal of consent/assent  
• If the subject becomes pregnant  
• If it is in the best interest of the subject, in the opi[INVESTIGATOR_689]  
• Termination of the study . 
When an event such as a family emergency, a transient illness (such as a cold) unrelated to 
SM, or a remediable act of non- compliance prevents a subject from participating in a 
scheduled visit, but the subject wishes to continue in the study, the Investigator will attempt 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956854]’s participation.  
If a subject is prematurely discontinued from participation in the study for any reason after 
SM administration, the Investigator must make every effort to perform the Final Visit 
assessments. 
4. DATA ANALYSIS  
Tabular summaries of the data collected during the study will be presented to provide a general description of the subjects studied and an overview of the efficacy and safety 
results.  Data from all sites will be combined in the computation of these summaries, and summaries will be presented by [CONTACT_1570].  Within each treatment group, summaries 
will also be presented by [CONTACT_704220] (< 30kg, ≥  30kg), where appropriate.  
All subjects randomized to Treatment 4, whether they are maintained on Treatment 4 or 
reduced to Treatment 3, will be analyzed under the Treatment 4 group.  Continuous 
variables will be summarized using descriptive statistics (number of subjects, mean, standard deviation [SD], median, and minimum and maximum values).  Categorical 
(nominal) variables will be summarized using frequency tables (number and percentage of 
subjects in each category).  If some values are missing, the percentages will sum to less than 100%.  
 
In addition to tabular summaries, subject data listings will be provided.  All data collected on CRF and from central laboratory will be presented in data listings.  Where appropriate, data will be summarized for each protocol -specified visit. Unscheduled data will be listed but not 
summarized.  
 
4.1 A NALYSIS POPULA TION S 
The enrolled population consists of all subjects with ICFs signed by [CONTACT_704221] (and 
IAFs signed by [CONTACT_748], where applicable).  
The safety population consists of all randomized subjects who receive at least 1 dose of SM.   
The intent -to-treat (ITT) population consists of all safety population subjects with at least [ADDRESS_956855] 1 PK measurement . 
The safety, ITT, restricted ITT, and PK populations are based on actual treatment received.   
Table 4.1. 1 provides these analysis populations for all randomized subjects.   
Listing 4. 1.1 provides inclusion and exclusion criteria violations for all randomized subjects.  
Listing 4. 1.2 gives analysis populations.   
 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956856] disposition will be summarized by [CONTACT_704222].  
The summary will include  
• number of subjects randomized  
• number of subjects completed the study  
• number of subjects discontinued from the study.  
Reasons for discontinuation will be summarized  by [CONTACT_704223].  Table 4.2.[ADDRESS_956857] demographic and baseline characteristics data will be summarized by [CONTACT_6490].  
Demographic/ baseline variables include sex, race, ethnicity, age, baseline height, baseline 
weight, and medical history.  Tables 4. 3.1, 4.3.2, and 4.3.3 will provide  tabular summaries of 
the demographic and basel ine variables for the safety, ITT, and restricted ITT  populations, 
except for medical history, which will be summarized for the safety population only  (Table 
4.3.4) .   
Listing 4.3.1 provides  sex, race, ethnicity, age, baseline height, baseline weight for all 
randomized subjects.   Listing 4.3.2 provides medical history for all randomized subjects.  
4.4 T REATMENT COMPLIANCE  AND EXPOSURE  
Records of SM and doses administered will be kept during the study.  The Clinical Research 
Associates (CRAs) will review drug accountability during investigational site visits and at the 
completion of the study.  
Duration of treatment exposure to SM will be summarized by [CONTACT_704224].  Summaries of exposure will be provided sepa rately 
for the Titration Period, Maintenance Period,  and combined Titration and Maintenance 
Periods (Table 4.4.1). 
For subjects randomized to Treatment 4, the number and percentage of subjects maintained 
on the target dose versus those reduced in dose (to Treatment 3 level) during the 
Maintenance Period will be provided (Table 4.4.2).  
4.5 P OTENTIAL EXCLUSIONS FROM ITT POPULATION  
Study data will be examined during the Data  Review (described below in section 4. 6) for 
potential exclusions from ITT population .  ICH E9 guideline outlines circumstances where it 
will usually be acceptable to omit subjects from the ITT population without causing bias.  
Some of the potential exclusions  in this study  are: 
 
• Subjects who violate the inclusion/exclusion criteria; 
• Subjects who fail to take at least one dose of study medication; 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 20 of 33  
 
• Subjects who do not provide any post -baseline data; 
• Enrollment of a subject who did not meet all inclusion/exclusion criteria which would 
affect subject safety or would negatively impact data integrity;  
• Use of any prohibited concomitant medication that may confound study results;  
• Subject dosing error that results in a serious adverse event;  
• Having any non- compliance issues raised by [CONTACT_704225];  
• Study visit or procedure conducted outside of required time frame that may negatively affect subject safety;  
• Subject visit/procedure falls outside of the window of time indicated by [CONTACT_704226].  
 
4.6 D ATA  REVIEW  
The checking and assessment of data to revisit the proposed methods of statistical analysis for the purpose of finalizing the planned analysis prior to the database lock  will be 
conducted.  The following lists some of the aspects of analysis that would be considered:  
 
• Checking of data for potential exclusions from ITT population ; 
• Precise definitions of analysis populations, especially which subjects will be included and which will be excluded;  
• Handling of missing data;  
• Pooling of centers;  
• Outlier identification and specific decisions taken on how these will be handled.  
 
The data review will be documented in agreed and signed meeting minutes, which wil l 
include a version of Listing 4.1.2 as appendix .  The data review will be included in Appendix 
13.1.  
5. EFFICACY ANALYSES  
5.1 G ENERAL CONSIDERATIONS AND STATISTICAL /ANALYTICAL ISSUES  
5.1.[ADDRESS_956858] available 
measurement/assessment before the first study drug application will be used as Baseline measure. 
 
5.1.2 Treatment Comparisons  
Statistical testing to compare treatment groups (overall and pairwise) will be performed for the ITT population only using appropriate statistical methods, as described in the efficacy 
subsections below.  Dose -response relationship will be assessed based on a review of the 
results of the complete set of pairwise comparisons of Treatment 1 vs. Treatment 2, 
Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4, without adjustment for 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 21 of 33  
 
multiple testing.  Given the small per- treatment group sample size for the study, the resulting 
p-values from the statistical testing will be used for descriptive purposes only (i.e., not for 
inferential purposes), primarily as an aid in the clinical interpretation of the efficacy results .   
5.1.3 Pooling of Centers  
As sample size per center will be small, all the centers will be pooled together for the 
analysis.  
5.1.4 Adjustments for Covariates  
Appropriate analysis of covariance (ANCOVA) will be conducted with treatment and weight 
group as the main factors and the baseline value as the covariate.  
5.1.5 Multiple Comparisons/Multiplicity  
Pairwise comparisons (Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and 
Treatment 3 vs. Treatment 4) will be performed but  without adjustment for multipl e 
comparisons.  
5.1.6 Examination of Subgroups  
Subgroup analyses for efficacy will be performed on categories of the following measures:  
• Gender  
• Race 
• Weight  
for the ITT population.  Subgroup analysis will comprise of summary statistics only, i.e. there 
will be no statistical testing.   
5.1.[ADDRESS_956859] (LOCF) technique will be used in the efficacy analysis for subjects who discontinue the study with post -randomization 
scores. 
5.[ADDRESS_956860] problem subscale of the NCBRF -TIQ after 6  weeks of maintenance 
treatment, the following primary  efficacy analysis  (Section 5.2.2) will be conducted.  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956861] (for the overall comparisons) and Wilcoxon rank -sum test (for the pairwise 
comparisons of Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 
vs. Treatment 4) for the ITT  population.  The Hodges -Lehmann estimators and associated 
95% confidence intervals will be calculated for the median differences between Treatment 1 
and Treatment 2, Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4 
(Hollander M, 1999).  Table [IP_ADDRESS] provides the primary efficacy results  for overall  and 
pairwise  comparisons  for NCBRF -TIQ conduct problem subscale for the ITT population.   
Table [IP_ADDRESS]  provides the summary statistics for NCBEF -TIQ conduct problem subscale for 
the restricted ITT population. 
Listing [IP_ADDRESS] provides NCBRF -TIQ conduct problem subscale data for the ITT population.   
5.3 S ECONDARY EFFICACY ANALYSES  
For the analysis of secondary efficacy variables, no statistical adjustment to the level of 
significance will be made for multiple endpoints and/or multiple comparisons.  
The secondary efficacy analyses for various secondary endpoints are as follows.  
5.3.1 Severity of Illness (CGI -S) 
The changes from baseline in the CGI -S at each post- baseline visit and endpoint will be 
compared among treatment groups using Kruskal -Wallis test (for the overall comparisons) 
and Wilcoxon rank -sum test (for the pairwise comparisons of Treatment 1 vs. Treatment 2, 
Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) for the ITT population.  The 
Hodges -Lehmann estimators and associated 95% confidence intervals will be calculated for 
the median differences between Treatment 1 and Treatment 2, Treatment 2 and Treatment 
3, and Treatment 3 and Treatment 4.  Table [IP_ADDRESS] provides secondary  efficacy results for  
overall and pairwise comparisons for  CGI-S for the ITT population.   Table [IP_ADDRESS] provides 
summary statistics for  CGI- S for  restricted ITT population. 
Listing [IP_ADDRESS] provides CGI-S data for the ITT population.   
5.3.2 Global Improvement (CGI-I)  
Actual CGI -I scores at each post -baseline visit and endpoint will be compared among 
treatment groups using Kruskal -Wallis test (for the overall comparisons) and Wilcoxon rank -
sum test (for the pairwise comparisons of Treatment 1 vs. Treatment 2, Treatment 2 vs. 
Treatment 3, and Treatment 3 vs. Treatment 4) for the ITT population.  The Hodges -
Lehmann estimators and associated 95% confidence intervals will be calculated for the 
median differences between Treatment 1 and Treatment 2, Treatment 2 and Treatment 3, 
and Treatment 3 and Treatment 4. Table [IP_ADDRESS] provides secondary  efficacy results for 
overall and pairwise comparisons for C GI-I for the ITT population . Table [IP_ADDRESS] provides 
summary statistics for CGI- I for the restricted ITT population. 
Listing [IP_ADDRESS] provides CGI-I data for the ITT population.   
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 23 of 33  
 
5.3.3 SNAP -IV Subscale: ADHD-Inattention 
The changes from baseline in the ADHD -Inattention ratings at each post -baseline visit and 
endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the overall 
comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of Treatment 1 vs. 
Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) for the ITT 
population.  The Hodges -Lehmann estimators and associated 95% confidence intervals will 
be calculated for the median differences between Treatment 1 and Treatment 2, Treatment 2 
and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS] provides secondary 
efficacy results for overall and pairwise comparisons for ADHD- Inattention for the ITT 
population.   Table [IP_ADDRESS] prov ides summary statistics for ADHD -Inattention for the restricted 
ITT population. 
Listing [IP_ADDRESS] provides ADHD- Inattention data for the ITT population .   
5.3.4 SNAP -IV Subscale:  ADHD- Hyperactivity/Impulsivity 
The changes from baseline in the ADHD -Hyperactivity/Impulsivity ratings at each post -
baseline visit and endpoint  will be compared among treatment groups using Kruskal -Wallis 
test (for the overall comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons 
of Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 
4) for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence 
intervals will be calculated for the median differences between Treatment 1 and Treatment 2, 
Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS] provides 
secondary efficacy results for overall and pairwise comparisons for ADHD- 
Hyperactivity/Impulsivity for the ITT population.   Table [IP_ADDRESS] provides summary statistics 
for ADHD- Hyperactivity/Impulsivity for the restricted ITT population . 
Listing [IP_ADDRESS] provides ADHD- Hyperactivity/Impulsivity data for the ITT population.   
5.3.5 SNAP -IV Subscale:  ADHD- Combined Scale  
The changes from baseline in the ADHD -Combined Scale ratings at each post -baseline visit 
and endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the 
overall comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of 
Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) 
for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence 
intervals will be calculated for the median differences between Treatment 1 and Treatment 2, Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS] provides 
secondary efficacy results for overall and pairwise comparisons for ADHD- Combined Scale 
for the ITT population.   Table [IP_ADDRESS] provides summary statistics for ADHD -Combined Scale 
for the restricted ITT population. 
Listing [IP_ADDRESS] provides ADHD- Combined Scale data for the ITT population.   
 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 24 of 33  
 
5.4 E XPLORATORY ANALYSES  
5.4.1 SNAP -IV: ODD Subscale 
The changes from baseline in the ODD subscale ratings at each post -baseline visit and 
endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the overall 
comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of Treatment 1 vs. 
Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) for the ITT 
population.  The Hodges -Lehmann estimators and associated 95% confidence intervals will 
be calculated for the median differences between Treatment 1 and Treatment 2, Treatment 2 
and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS] provides exploratory 
analysis results for overall and pairwise comparisons for ODD subscale for the ITT 
population.   Table [IP_ADDRESS] prov ides summary statistics for ODD subscale  for the restricted 
ITT population. 
Listing [IP_ADDRESS] provides ODD subscale data for the ITT population.   
5.4.2 The NCBRF -TIQ Subscales  
[IP_ADDRESS] NCBRF -TIQ: Positive Social Subscale  
The changes from baseline in the positive social  subscale ratings at each post -baseline visit 
and endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the 
overall comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of 
Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) 
for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence 
intervals will be calculated for the median differences between Treatment 1 and Treatment 2, 
Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides 
exploratory analysis results for overall and pairwise comparisons for positive social subscale 
for the ITT population.   Table [IP_ADDRESS].2 provides summary statistics for positive social  
subscale for the restricted ITT population. 
Listing [IP_ADDRESS].1 provides positive social subscale data for the ITT population.   
[IP_ADDRESS] NCBRF -TIQ: Overly Sensitive Subscale 
The changes from baseline in the overly sensitive  subscale ratings at each post -baseline 
visit and endpoint  will be compared among treatment groups using Kruskal -Wallis test (for 
the overall comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of 
Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) 
for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence 
intervals will be calculated for the median differences between Treatment 1 and Treatment 2, 
Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides 
exploratory analysis results for overall and pairwise comparisons for overly sensitive 
subscale for the ITT population.   Table [IP_ADDRESS].2 provides summary statistics for overly 
sensitive subscale for the restricted ITT population. 
Listing [IP_ADDRESS].1 provides overly sensitive subscale data for the ITT population.   
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 25 of 33  
 
[IP_ADDRESS] NCBRF -TIQ: Oppositional Behavior Subscale  
The changes from baseline in the oppositional behavior subscale ratings at each post -
baseline visit and endpoint  will be compared among treatment groups using Kruskal -Wallis 
test (for the overall comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons 
of Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 
4) for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence 
intervals will be calculated for the median differences between Treatment 1 and Treatment 2, 
Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides 
exploratory analysis results for overall and pairwise comparisons for oppositional behavior 
subscale for the ITT population.   Table [IP_ADDRESS].2 provides summary statistics for oppositional 
behavior subscale for the restricted ITT population. 
Listing [IP_ADDRESS].1 provides oppositional behavior subscale  data for the ITT population.   
[IP_ADDRESS] NCBRF -TIQ: Hyperactivity Subscale  
The changes from baseline in the hyperactivity subscale ratings at each post -baseline visit 
and endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the 
overall comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of 
Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) 
for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence 
intervals will be calculated for the median differences between Treatment 1 and Treatment 2, 
Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides 
exploratory analysis results for overall and pairwise comparisons for hyperactivity subscale  
for the ITT population.   Table [IP_ADDRESS].2 provides summary statistics for hyperactivity subscale 
for the restricted ITT population. 
Listing 5.4.2. 4.1 provides hyperactivity subscale data for the ITT population.   
[IP_ADDRESS] NCBRF -TIQ: Inattention Subscale  
The changes from baseline in the inattention subscale ratings at each post -baseline visit and 
endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the overall 
comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of Treatment 1 vs. 
Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) for the ITT 
population.  The Hodges -Lehmann estimators and associated 95% confidence intervals will 
be calculated for the median differences between Treatment 1 and Treatment 2, Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides exploratory 
analysis results for overall and pairwise comparisons for inattention subscale for the ITT 
population.   Table [IP_ADDRESS].2 prov ides summary statistics for inattention subscale  for the 
restricted ITT population. 
Listing [IP_ADDRESS].1 provides inattention subscale data for the ITT population.   
[IP_ADDRESS] NCBRF -TIQ: Withdrawal/Dysphoria Subscale  
The changes from baseline in the withdrawal/dysphoria subscale ratings at each post -
baseline visit and endpoint  will be compared among treatment groups using Kruskal -Wallis 
test (for the overall comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 26 of 33  
 
of Treatment 1 vs. Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 
4) for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence 
intervals will be calculated for the median differences between Treatment 1 and Treatment 2, 
Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides 
exploratory analysis results for overall and pairwise comparisons for withdrawal/dysphoria 
subscale for the ITT population.   Table [IP_ADDRESS].2 provides summary statistics for 
withdrawal/dysphoria subscale for the restricted ITT population. 
Listing [IP_ADDRESS].1 provides withdrawal/dysphoria subscale data for the ITT population.   
[IP_ADDRESS] NCBRF -TIQ: Disruptive Behavior Disorder (DBD) Subscale  
The changes from baseline in the DBD subscale ratings at each post -baseline visit and 
endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the overall 
comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of Treatment 1 vs. 
Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) for the ITT population.  The Hodges -Lehmann estimators and associated 95% confidence intervals will 
be calculated for the median differences between Treatment 1 and Treatment 2, Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides exploratory 
analysis results for overall and pairwise comparisons for DBD subscale for the ITT 
population.   Table [IP_ADDRESS].2 prov ides summary statistics for DBD subscale for the restricted 
ITT population. 
Listing [IP_ADDRESS].1 provides DBD subscale data for the ITT population.   
[IP_ADDRESS] NCBRF -TIQ: ADHD-Total Score  
The changes from baseline in the ADHD -Total Score at each post -baseline visit and 
endpoint  will be compared among treatment groups using Kruskal -Wallis test (for the overall 
comparisons) and Wilcoxon rank -sum test (for the pairwise comparisons of Treatment 1 vs. 
Treatment 2, Treatment 2 vs. Treatment 3, and Treatment 3 vs. Treatment 4) for the ITT 
population.  The Hodges -Lehmann estimators and associated 95% confidence intervals will 
be calculated for the median differences between Treatment 1 and Treatment 2, Treatment 2 and Treatment 3, and Treatment 3 and Treatment 4.  Table  [IP_ADDRESS].1 provides exploratory 
analysis results for overall and pairwise comparisons for ADHD- Total Score for the ITT 
population.   Table [IP_ADDRESS].2 prov ides summary statistics for ADHD- Total Score for the 
restricted ITT population. 
Listing [IP_ADDRESS].[ADDRESS_956862] -baseline visit and endpoint will be compared among treatment 
groups using analysis of covariance (ANCOVA) with treatment and weight group as the main 
factors and the baseline value as the covariate.   Table 5.5.[ADDRESS_956863] problem subscale for the ITT population . 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 27 of 33  
 
6. SAFETY ANALYSES 
The safety and tolerability endpoints will be summarized for the safety population according 
to the treatment actually received.  Statistical testing will be performed for some of the safety endpoints, but the resulting p -values will be used for descriptive purposes only.  
 Safety will be assessed by [CONTACT_345683] , vital signs, clinical laboratory tests, 
physical examinations, and electrocardiograms (ECG), as well as by [CONTACT_345684] -Angus 
scale, the Barnes Akathisia scale, and the Abnormal Involuntary M ovement  Scale (AIMS).  
6.1 A DVERSE EVENTS   
AEs will be classified into standardized medical terminology from the verbatim description 
(Investigator term) using the Medical Dictionary for Regulatory Activities (MedDRA).  
Although a MedDRA term for a subject may be reported more than once, that subject will be counted only once in the incidence count for that MedDRA term.  AEs will be presented in 
the summary tables by [CONTACT_364398].   
Verbatim description and all MedDRA level terms, including the lower level terms, for all AEs 
will be contained in the subject data listings (Listing 6.1.1).  
6.1.[ADDRESS_956864] conservative interpretation will be assumed.  
AEs will be summarized for each treatment group by [CONTACT_704227].   
Table [IP_ADDRESS] will provide overall incidence of AEs for the Safety population.  Table [IP_ADDRESS] will provide an incidence summary of AEs by [CONTACT_1196], and Preferred Term for the Safety population.   
Table [IP_ADDRESS] will provide an incidence summary of AEs by [CONTACT_1196], Preferred Term, and Relationship to Study Drug for the Safety population.  If a subject had two or more adverse events in the same system organ class (or with the same preferred term) with different relationships to study drug, then the event with the closest relationship to study 
drug will be used for that subject.  
Table [IP_ADDRESS] will provide an incidence summary of AEs by [CONTACT_1196], Preferred 
Term, and Severity for the Safety population.  If a subject had two or more adverse events in 
the same system organ class (or with the same preferred term) with different levels of 
severity, then the event with the worst severity will be  used for that subject.   
6.1.2 By [CONTACT_704217]/Baseline Variables 
Tables similar to those for the Overall Study ([IP_ADDRESS] - [IP_ADDRESS]) will be presented for the 
demographic/baseline variables listed below:    
Sex – Tables [IP_ADDRESS] - 6.1.2 .4 
Race – Tables [IP_ADDRESS] - [IP_ADDRESS]  
Ethnicity – Tables [IP_ADDRESS] - [IP_ADDRESS]  
Weight (<30kg and ≥ 30kg) – Tables [IP_ADDRESS]  - [IP_ADDRESS] . 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 28 of 33  
 
6.1.3 Deaths, Serious AEs, and Other Significant AEs  
Listings (and tabular summaries, if warranted) of deaths, SAEs, and other significant AEs, 
including AEs resulting in treatment discontinuation, study drug dose reduction,  and study 
drug interruption will be provided ( Listings [IP_ADDRESS] through [IP_ADDRESS] ). 
6.[ADDRESS_956865] results will be presented.   
Laboratory testing will be broken down by [CONTACT_704228], Chemistry, and Urinalysis tests .  
Tables 6.2.1 through 6.2.4 will provide summaries for Hematology and Chemistry 
respectivel y and associated shift tables.  Listings 6.2.1 through 6.2.4 will provide by -patient 
listing for hematology, chemistry, urinalysis , and urine pregnancy tests  respectively. 
6.3 V ITAL SIGNS, HEIGHT , WEIGHT AND BMI 
Summary table of vital signs (HR, blood pressure, temperature, respi[INVESTIGATOR_697]) and height 
and weight will be presented by [CONTACT_690371]. This summary table  will also include 
change from  baseline by [CONTACT_10659].  Descriptive summary statistics (mean, SD, 
median, and range) for vital sign data and height  and weight will be evaluated by [CONTACT_6490].  Table 6.3.1 provides the summary table for vital signs, heights, weights  and BMI . 
Individual listings will also be provided for these parameters (Listing 6.3.1).   
6.4 ECG  RESULTS  
Table 6.4.1 provides overall ECG findings (normal, abnormal not clinically significant, or 
abnormal clinically significant).  Table 6.4.2 summarizes ECG results (both actual values and change from baseline values) by [CONTACT_704229]: PR Interval (msec), QRS Duration (msec), QT Interval (msec), and QTcF Interval (msec).  Table 6.4.[ADDRESS_956866] -
Baseline Visits for qualitative ECG parameters.  
Table 6.4.4 provides the number and percentage of subjects with any QTcF value >= 450 msec for all assessments made during the study as well as by [CONTACT_704230].   This table also provides the number and percentage of subjects with any change from baseline in the QTcF of >= 30 – 59 msec as well as >= 60 msec over all 
assessments made during the study as well as by [CONTACT_3232].  
Listing 6.4.1 provides ECG Findings.  
6.5 P HYSICAL EXAMINATION  
Findings from the physical examinations will be summarized through 2 by 2 shift tables that, for each system or area examined, compare the normal/abnormal finding at screening to the 
normal/abnormal finding at the Final Visit. Table 6.5.1 gives the results of physical 
examination.  
Listing 6.5.1 provides physical examination findings.  
6.6 C ONCOMITANT MEDICATIONS  
A table (Table 6.6.1)  summarizing frequencies of current use of concomitant medications  will 
be presented for the safety  population and its treatment group subsets.  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 29 of 33  
 
Listing 6.6.1 provides the details of concomitant medications , and will summarize 
medications by [CONTACT_704231], route of administration, 
frequency, dates, and indication. 
6.7 O THER SAFETY ANALYSES  FOR EXTRAPYRAMIDAL SYMPTOMS (EPS) 
6.7.1 Simpson-Angus Scale (SAS) 
Listing [IP_ADDRESS]  provides subject -wise SAS scores for each visit.  The occurrence of 
neurological side effects will be assessed by [CONTACT_704232] -baseline visits . 
For each item on the SAS scale, the number (and percentage) of subjects with a worse score at any post -baseline visit, compared to baseline, will be presented in Table 6.7.1. 1. 
6.7.2 Barnes Akathisia Scale (BAS) 
Listing [IP_ADDRESS]  provides subject -wise BAS scores for each visit.  The occurrence of 
neurological side effects will be assessed by [CONTACT_704233] -baseline visits.  
For each item on the BAS scale, the number (and percentage) of subjects with a worse 
score at any post -baseline visit, compared to baseline, will be presented in Table 6.7.2. 1. 
6.7.3 Abnormal Involuntary Movement Scale (AIMS)  
Listing [IP_ADDRESS]  provides subject -wise AIMS scores for each visit.  The occurrence of 
neurological side effects will be assessed by [CONTACT_704232] -baseline visits.   
For each item on the AIMS scale, the number (and percentage) of subjects with a worse 
score at any post -baseline visit, compared to baseline, will be presented in Table 6.7.3. 1. 
7. DATA SAFETY MONITORING BOARD (DSMB) 
A Data Safety Monitoring Board (DSMB) will monitor the conduct and safety of the study on 
a quarterly basis.  Appendix 13.[ADDRESS_956867] OR PLANNED ANALYSES FROM THE 
PROTOCOL  
Describe any changes to statistical methods section in the protocol before database lock . 
Provide the reasons for the changes. Some changes may require an amendment to the 
protocol.  
Any changes to the statistical analysis plan after database lock should be addressed in a 
separate document. That document will be approved separately and included as an 
addendum to the final SAP.
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 30 of 33  
 
8. PROGRAMMING  SPECIFICATIONS  
All summary tables, data listings, figures and other statistical output will be produced with 
the SAS system (version 9.2) and will be incorporated into a MS Word document for easy 
integration into the CSR production process.  Summary t ables, data listings, and figures will 
be produced in the order that they appear in the textual sections of the plan.  
The SAS generated output will adhere to the following specifications.  
8.1 FORMAT OF TABLES AND LISTINGS  
Tables and listings will be produced in landscape orientation.  To ensure the print window is usable for both A4 paper size (21 x 29.7 cm; 8.27 x 11.69 inches) and US letter paper size 
(21.59 x 27.94 cm; 8.5 x 11 inches), the following page size and margins will be used:  
 
• Print window: 15.88 x 22.61 cm (6.25 x 8.9 inches)  
• Top and bottom margins approximately:       
   A4: 2.54 cm (1 inch);       
   US: 2.85 cm (1.12 inches).  
• Left and right margins approximately:       
   A4: 3.56 cm (1.4 inches);      
   US: 2.54 cm (1 inch).  
 
A fixed space font (Courier New or SAS Monospace) with point size 9 will be used for all 
tables and listings.  Under very limited circumstances , reducing the point size to 8 or 7.5 for 
a listing  may be considered if the reduction is absolutely necessary to fit all columns on one 
page, and splitting the listing into two or more pages is not a viable option.  
8.1.1 Title of a Table/Listing  
The first line of the title will immediately follow the header line (i.e., no blank line in between).  The title of a table/listing will be centered.  The first letter of each imperative word will be capi[INVESTIGATOR_057].  Up to 6 lines of the page are available to enter the title.   (Note:  There will be no 
blank title lines.)  
The title will state the table/listing number, describe the table/listing briefly, and describe the 
population that is included in the table/listing, i.e.:  
   Line 1 of title:  Table xx.x.  
   Line 2 of title:  Main title  
   Line 3 of title (optional):  Subtitle  
   Line 4 of title:  XXX Population  
If Line 3 is not utilized, then Line 4 will be moved up.   
The table/listing numbering will be consecutive, with no skippi[INVESTIGATOR_704214] .  Up to  5 levels 
of numbering (i.e., xx.x.x.x.x or xx.x .x.x.x) are allowed.  If the same table/listing is produced 
for multiple analysis populations (e.g.,  ITT Population and restricted ITT  Population) or data 
imputations (e.g., Observed Data and LOCF Data), the resulting multiple tables/listings should share the same table/listing number, except for the last level, which will be 
consecutively numbered 1, 2, 3,…, t where t is the total number of tables/listings generated (e.g., 4.2.1 for ITT Population and 4.2.2 for restricted ITT  Population).  
For numeric variables, the appropriate unit will be added to the column heading.  For 
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.[ADDRESS_956868]  number, visit, and time of 
collection (if available) . 
Verbose titles should be avoided.  In the case where a title line is too wide for the page, then 
the title line will wrap on to the next line, and all subsequent lines will increment by [CONTACT_31806].  
If there is stratification or subgroupi[INVESTIGATOR_704215] (e.g., Sex) with summaries to be 
presented for each subgroup on a separate page, the subgroupi[INVESTIGATOR_704216] a page (e.g., 
Males) will appear, left -aligned with the body of the table/listing, on the line immediately 
below the last title line.  
There will be a solid horizontal line across the page immediately below the last title line (or 
the subgroup label, if present), as wide as the body of the table/listing.  
8.1.2 Footnotes to a Table/Listing  
There will be a solid horizontal line across the page, as wide as the upper horizontal line, 
signifying the end of the body of the table/listing for that page.  Footnotes are immediately 
below this horizontal line, with the exception of the documentation line, which appears on the bottom line of the page.  Footnotes will be left -aligned with the body of the table/listing.  If the 
footnote is a complete sentence, then the usual sentence construction will be followed.  If the footnote is a single word or a phrase, then the first letter of the first word will be 
capi[INVESTIGATOR_057].  Up to [ADDRESS_956869] footnote will name [CONTACT_704235](s) where the data used in the table came from, in the following format:  
   Source:  Listing xx.x  
Footnotes that apply to the table/listing in general will precede footnotes that apply to a specific item (e.g., title line, row label, column header, specific count, descriptive statistic, p-
value, or data) on the table/listing.  An example of a general footnote is as follows:  “A subject  who has the same TESS more than once during the study was counted once in the 
total number of subject s per system organ class calculation.”  An example of an item -specific 
footnote is as follows:  “
*Significant at the 0.050 level”.  
The use of superscripting in footnotes is not recommended.  If there is only one item -specific 
footnote on a table/listing, one of the symbols #, *, and @ will be used to tag the item, with a single blank space between the item and the symbol.  In general, the asterisk will be reserved for tagging items related to the presentation of p- values.  The footnote will begin 
with the symbol, followed by a single blank space, and then the footnote text, e.g.:  
# footnote text here   
If there are multiple item -specific footnotes on a table/listing, “(x)” will be used to tag each 
item, with the x’s being either all numbers (1, 2, 3, etc.) or all letters (a, b, c, etc.), and with a 
single blank space between the item and the corresponding “(x)”.  The footnote will begin with the “(x)”, followed by a single blank space, and then the footnote text, e.g.:  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 32 of 33  
 
   (x) footnote text here  
The use of self -explanatory or commonly used abbreviations to tag an item for footnoting 
may supersede the conventions described in the two preceding paragraphs.  Examples of 
commonly used abbreviations include the following:  H=Above upper normal limit, W=Within normal limits, and L=Below lower normal limit; ND=Not done; N/A=Not applicable; and 
NAV=Not available.  Note that in these examples, the letters are not in parentheses and have the equal sign connecting the letters with the footnote text.  
When a general footnote exceeds one line in length, the text will wrap on to the next line, with no indentation if there is only one general footnote (excluding the source footnote) and 
with two -space indentation if there are more than one general footnote.  When an item -
specific footnote exceeds one line in length, the lines after the first one will be left -aligned 
with the first line, minus the “(x)”, e.g.:  
(x) first line of footnote text here  
       second line of footnote text here  
 
8.1.[ADDRESS_956870] the following Header:  
Supernus Pharmaceuticals, Inc.       Page x of xx                             
Protocol No.: 810P201   
and the following Footer:  
Program:  Programname.sas  DDMMMYYYY HH:MM       Produced: DDMMMYYYY HH:MM   
8.[ADDRESS_956871] 
further.  P -values will be given with 3 decimals.   P -values < .001 will be shown as “<0.001”.  
All fractional numeric values will be printed with a zero to the left of the decimal point (e.g., 
0.12, 0.3 etc.).  Unless otherwise specified, percentage values will be printed with one digit 
to the right of the decimal point (e.g., 52.3%, 8.9% etc.).   Dates will be displayed using the 
ISO 8601 format as required for Clinical Data Interchange Standards Consortium  (CDISC) 
standards.  Dates will be presented as DDMMMYYYY and time values will be presented as 
HH:MM:SS or HH:MM. 
8.3 C ODING LISTS 
The coding of the data is performed with the following coding lists:  
 
Data  Coding list  / Version  
Adverse events  MedDRA / Version 11.1  
Medication names  WHO Drug Dictionary/ December 2008  
Supernus Pharmaceuticals, Inc.                       CONFIDENTIAL                                 31 AUG  2009  
Statistical Analysis Plan (Protocol: 810P201)  FINAL V ersion 1.0                           Page 33 of 33  
 
9. SUMMARY TABLES, DATA LISTINGS AND FIGURES (TLFS) 
Shells of summary tables and data listings are presented as separate documents in order to 
provide a framework for the display of data and results of statistical analyses for this study.  These shells may change due to unforeseen circumstances.   There are no shells for figures.  
 
10. REFERENCES  
Aman MG, Tasse MJ, Rojahn J, Hammer D.  The Nisonger CBRF: A child behavior rating form for children with developmental disabilities.  Res. Devel. Disabil. 1996; 17:41- 57. 
 
Tasse MJ, Aman MG, Hammer D, Rojahn J. The Nisonger Child Behavior Rating Form: Age 
and gender effects and norms. Res. Devel. Disabil. 1996; 17:59 -75. 
 Guy W.  Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology.  
Rockville, MD.  U.S. National Institute of Health, Psychopharmacology Research Branch. 
1976, pp. 217- 222. 
 
Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, et al.  Clinical 
relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment.  J. Amer. Acad. Child Adolesc. Psychiatry 2001; 
40:[ADDRESS_956872]. 1970; 212:11- 19. 
 Barnes TRE. A rating scale for drug -induced akathisia. Br. J. Psychiatry 1989; 154:672 -676. 
Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary 
movement scale. Hosp. Commun. Psychiatry 1988; 39:1172- 1177.  
 
11. FINAL VERSION REVISION HISTORY  
Date o f Revision  Author  Summary of C hange(s) From Final Version 1 .0 
   
   
   
   
 
12. APPENDICES  
12.1 A PPENDIX I: DATA REVIEW MEETING MINUTES  
12.2 A PPENDIX II: REPORT TO THE FIRST MEETING OF THE DSMB 
12.3 A PPENDIX III: REPORT TO THE SECOND MEETING OF THE DSMB 